MedPath

Xiamen Lp Pharmaceutical Co., Ltd.

Xiamen Lp Pharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
Holding
Established
2012-11-02
Employees
101
Market Cap
-
Website
http://www.lppharma.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 2:1
Phase 3:1

Drug Approvals

2

FDA:2

Drug Approvals

Pramipexole Dihydrochloride

Approval Date
Jun 16, 2021
FDA

Clonidine Hydrochloride

Approval Date
Oct 27, 2020
FDA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 3
1 (50.0%)

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

Phase 3
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Drug: IV Palonosetron 0.25 mg
First Posted Date
2022-01-20
Last Posted Date
2023-01-20
Lead Sponsor
Xiamen LP Pharmaceutical Co., Ltd
Target Recruit Count
328
Registration Number
NCT05199818
Locations
🇺🇸

Ironwood Cancer & Research Centers, Chandler, Arizona, United States

🇺🇸

Pacific Cancer Medical Center, Anaheim, California, United States

🇺🇸

Watson Clinic, Lakeland, Florida, United States

and more 10 locations

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

First Posted Date
2020-10-19
Last Posted Date
2025-03-24
Lead Sponsor
Xiamen LP Pharmaceutical Co., Ltd
Target Recruit Count
22
Registration Number
NCT04592198
Locations
🇺🇸

Pacific Cancer Medical Center, Inc., Anaheim, California, United States

🇺🇸

Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida, United States

🇺🇸

Edward H. Kaplan MD & Associates, Skokie, Illinois, United States

and more 4 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.